This document discusses opportunities for developing medical cannabis-based drugs, including over 100 potential clinical applications. It outlines two major cannabinoids - THC and CBD - and their therapeutic effects. Developing cannabis-based medicines requires navigating regulations as cannabis is currently a Schedule I drug. Preclinical studies must address regulatory concerns and mimic future clinical use. Successful drug development requires collaboration between clinical/regulatory experts, scientists, and those who can secure intellectual property protection and financing.